Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
14 06 2022
14 06 2022
Historique:
received:
15
11
2021
accepted:
25
01
2022
pubmed:
18
2
2022
medline:
7
6
2022
entrez:
17
2
2022
Statut:
ppublish
Résumé
Clinical success with intravenous (IV) oncolytic virotherapy (OV) has to-date been anecdotal. We conducted a phase 1 clinical trial of systemic OV and investigated the mechanisms of action in responding patients. A single IV dose of vesicular stomatitis virus (VSV) interferon-β (IFN-β) with sodium iodide symporter (NIS) was administered to patients with relapsed/refractory hematologic malignancies to determine safety and efficacy across 4 dose levels (DLs). Correlative studies were undertaken to evaluate viremia, virus shedding, virus replication, and immune responses. Fifteen patients received VSV-IFNβ-NIS. Three patients were treated at DL1 through DL3 (0.05, 0.17, and 0.5 × 1011 TCID50), and 6 were treated at DL4 (1.7 × 1011 TCID50) with no dose-limiting toxicities. Three of 7 patients with T-cell lymphoma (TCL) had responses: a 3-month partial response (PR) at DL2, a 6-month PR, and a complete response (CR) ongoing at 20 months at DL4. Viremia peaked at the end of infusion, g was detected. Plasma IFN-β, a biomarker of VSV-IFNβ-NIS replication, peaked between 4 hours and 48 hours after infusion. The patient with CR had robust viral replication with increased plasma cell-free DNA, high peak IFN-β of 18 213 pg/mL, a strong anti-VSV neutralizing antibody response, and increased numbers of tumor reactive T-cells. VSV-IFNβ-NIS as a single agent was effective in patients with TCL, resulting in durable disease remissions in heavily pretreated patients. Correlative analyses suggest that responses may be due to a combination of direct oncolytic tumor destruction and immune-mediated tumor control. This trial is registered at www.clinicaltrials.gov as #NCT03017820.
Identifiants
pubmed: 35175355
pii: 484092
doi: 10.1182/bloodadvances.2021006631
pmc: PMC9198941
doi:
Substances chimiques
Interferon-beta
77238-31-4
Banques de données
ClinicalTrials.gov
['NCT03017820']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3268-3279Subventions
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097274
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA186781
Pays : United States
Informations de copyright
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Adv Virol. 2012;2012:805629
pubmed: 22400027
Expert Opin Biol Ther. 2016;16(1):15-32
pubmed: 26457362
Hum Gene Ther Clin Dev. 2016 Sep;27(3):111-22
pubmed: 27532609
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
BioDrugs. 2019 Oct;33(5):485-501
pubmed: 31321623
J Immunother Cancer. 2018 Dec 4;6(1):140
pubmed: 30514385
Vet J. 1999 May;157(3):239-60
pubmed: 10328837
Mol Ther. 2011 May;19(5):886-94
pubmed: 21364541
JAMA Oncol. 2017 Jun 01;3(6):841-849
pubmed: 27441411
Nucl Med Commun. 2008 Mar;29(3):193-207
pubmed: 18349789
Mayo Clin Proc. 2014 Jul;89(7):926-33
pubmed: 24835528
Oncotarget. 2017 Jul 25;8(41):71249-71284
pubmed: 29050360
Cancers (Basel). 2021 Mar 09;13(5):
pubmed: 33803211
J Clin Oncol. 2002 May 1;20(9):2251-66
pubmed: 11980996
J Virol. 2008 Dec;82(24):12104-15
pubmed: 18829743
Nat Biotechnol. 2012 Jul 10;30(7):658-70
pubmed: 22781695
J Cutan Med Surg. 2019 Sep/Oct;23(5):537-544
pubmed: 31353944
J Hematol Oncol. 2020 Dec 3;13(1):164
pubmed: 33272302
Nat Rev Drug Discov. 2021 Feb;20(2):101-124
pubmed: 33277608
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Onco Targets Ther. 2019 Feb 07;12:1085-1094
pubmed: 30799938
J Natl Cancer Inst. 2009 May 20;101(10):708-20
pubmed: 19436029
Hum Gene Ther Clin Dev. 2017 Jun;28(2):108-115
pubmed: 28514874
EJNMMI Res. 2017 Oct 27;7(1):90
pubmed: 29080017
Mol Ther. 2016 Dec;24(12):2109-2117
pubmed: 27669655
PLoS One. 2013 Sep 11;8(9):e73759
pubmed: 24040057
Hum Gene Ther Clin Dev. 2013 Dec;24(4):174-81
pubmed: 24219832
Crit Rev Oncol Hematol. 2016 Mar;99:214-27
pubmed: 26811013
Mol Ther. 2016 Feb;24(2):306-317
pubmed: 26647825
Blood. 2001 Jan 15;97(2):523-7
pubmed: 11154232
Mol Cancer Ther. 2018 Jan;17(1):316-326
pubmed: 29158470
Future Virol. 2017 Apr;12(4):193-213
pubmed: 29387140
Theranostics. 2018 Jun 24;8(14):3918-3931
pubmed: 30083270
Drug Des Devel Ther. 2017 Jun 13;11:1719-1728
pubmed: 28670108
J Immunother Cancer. 2019 Jun 6;7(1):145
pubmed: 31171039
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
J Gen Virol. 2017 Dec;98(12):2895-2911
pubmed: 29143726
J Virol. 2004 Dec;78(23):12747-61
pubmed: 15542627
Sci Rep. 2017 Apr 19;7(1):946
pubmed: 28424464
Drugs. 2016 Jan;76(1):147-54
pubmed: 26620366
Curr Opin Mol Ther. 2010 Aug;12(4):412-20
pubmed: 20677092
J Oncol Pract. 2017 Aug;13(8):487-492
pubmed: 28796966
Leukemia. 2012 Aug;26(8):1870-8
pubmed: 22425894
Trends Mol Med. 2004 May;10(5):210-6
pubmed: 15121047
Sci Rep. 2013;3:2375
pubmed: 23921465
J Virol. 2013 Apr;87(7):3752-9
pubmed: 23325695